ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Da-pag-li-flo-zin is Well Tolerated in Hospitalized Patients
June 28, 2021DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19. -
Update on the DARE-19 Phase III Trial for Farxiga in COVID-19
April 13, 2021AstraZeneca and Saint Luke’s Mid America Heart Institute announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalized with COVID-19 who are at ... -
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
April 26, 2020AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin).
Pharma Sources Insight January 2025
